With physiological wearable biosensors now widespread consumer products and living in a post-COVID-19 world there is a rapid shift away from traditional centralized clinical trials and towards decentralized clinical trials (DCTs) and hybrid clinical trials (HCTs).
In DCTs and HCTs technologies are used to monitor the patient in the form of wearable biosensors or point of care invitro-diagnostics. The key requirement is that these technologies are operable by the patient and connected to the Cloud so that the patient data can securely send data to the Cloud enabling the patient's clinical status to be remotely monitored.
#ZP
#biosensors
facebooktwitterlinkedin
